Oramed Pharmaceuticals
ORMP
56 hedge funds and large institutions have $5.99M invested in Oramed Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 6 closing their positions.
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
111% more call options, than puts
Call options by funds: $158K | Put options by funds: $75K
12% more funds holding
Funds holding: 50 → 56 (+6)
0.01% more ownership
Funds ownership: 5.69% → 5.7% (+0.01%)
8% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 13
27% less capital invested
Capital invested by funds: $8.15M → $5.99M (-$2.16M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Rathbones Group
Liverpool,
United Kingdom
|
+$913K |
| 2 |
Goldman Sachs
New York
|
+$197K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$85.9K |
| 4 |
LPL Financial
San Diego,
California
|
+$66.1K |
| 5 |
Squarepoint
New York
|
+$58.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$281K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$238K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$234K |
| 4 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$216K |
| 5 |
SRC
Samson Rock Capital
London,
United Kingdom
|
-$132K |
ORMP Hedge Fund Activity: Q3 2023 in Review
56 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q3 2023, worth a combined $5.99M — down 27% from $8.15M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ORMP positions and 6 closed out — a net gain of 8 holders — while 12 added to existing stakes and 13 trimmed.
The largest buyer was Rathbones Group, opening a new position worth an estimated $913K. The largest seller was Millennium Management, exiting entirely with an estimated $281K sold.
- 56 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q3 2023, up from 50 in Q2 2023.
- Funds reported $5.99M of Oramed Pharmaceuticals stock for Q3 2023, down 27% quarter-over-quarter.
- 14 funds opened new Oramed Pharmaceuticals positions in Q3 2023 and 6 closed out, a net change of +8 holders.
- The largest Oramed Pharmaceuticals buyer in Q3 2023 was Rathbones Group, an estimated $913K added.
- The largest Oramed Pharmaceuticals seller in Q3 2023 was Millennium Management, an estimated $281K sold.
Based on aggregated 13F filings for Q3 2023.